Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALPG | P10696 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1246277 | 0.82 | MMP1 (0.50) | MMP1MMP3MMP8ANPEPCA12 | |
| SCHEMBL32685957 | 0.78 | MMP1 (0.38) | MMP1MMP3MMP8ANPEPCA12 | |
| SCHEMBL9346545 | 0.73 | MMP1 (0.40) | MMP1MMP3MMP8CA12CA1 | |
| SCHEMBL1246279 | 0.70 | MMP1 (0.46) | MMP1MMP3MMP8ANPEPCA12 | |
| SCHEMBL5691755 | 0.70 | ANPEP (0.44) | MMP1MMP3MMP8ANPEPCA12 | |
| Phosphoramidic Acid SCHEMBL29069931 | 0.68 | MMP1 (0.45) | MMP1MMP3MMP8ANPEPCA12 | |
| SCHEMBL10527462 | 0.68 | PHGDH (0.39) | CA12SMN1; SMN2KMT2A | |
| SCHEMBL3363445 | 0.68 | ALDH1A1 (0.38) | MMP1MMP3MMP8SMN1; SMN2CYP2D6 | |
| SCHEMBL1615661 | 0.65 | MMP1 (0.42) | MMP1MMP3MMP8ANPEPCA12 | |
| SCHEMBL329843 | 0.64 | MMP1 (0.50) | MMP1MMP3MMP8ANPEPCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3238737-B1 | MEANS AND METHODS FOR COUNTERACTING MUSCLE DISORDERS | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2022-04-06 | — | — | EP | claimed |
| US-11274299-B2 | Methods and means for treating DNA repeat instability associated genetic disorders | VICO THERAPEUTICS B.V. (NL) | 2022-03-15 | — | — | US | claimed |
| US-20200140857-A1 | Methods and means for treating DNA repeat instability associated genetic disorders | VICO THERAPEUTICS B.V. (NL) | 2020-05-07 | — | — | US | claimed |
| EP-3265581-B1 | SIMULTANEOUS DETECTION OF OLIGONUCLEOTIDES, A KIT AND A USE RELATED THERETO | AXOLABS GMBH (DE) | 2019-05-01 | — | — | EP | claimed |
| EP-2614827-B1 | Means and methods for counteracting muscle disorders | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2017-06-28 | — | — | EP | claimed |
| EP-2426203-B1 | Agents useful in treating facioscapulohumeral muscular dystrophy | Université de Mons (BE) | 2016-07-13 | — | — | EP | claimed |
| EP-2421971-B1 | OLIGONUCLEOTIDE COMPRISING AN INOSINE FOR TREATING DMD | BIOMARIN TECHNOLOGIES B V (NL) | 2016-07-06 | — | — | EP | claimed |
| EP-2203173-B1 | MEANS AND METHODS FOR COUNTERACTING MUSCLE DISORDERS | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2015-12-23 | — | — | EP | claimed |
| EP-2331950-B1 | NANOSTRUCTURED MICROELECTRODES AND BIOSENSING DEVICES INCORPORATING THE SAME | UNIV TORONTO (CA) | 2014-07-23 | — | — | EP | claimed |
| EP-1606407-B1 | MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2013-12-18 | — | — | EP | claimed |
| US-20110092380-A1 | IMPROVED MOLECULAR-BIOLOGICAL PROCESSING EQUIPMENT | FEBIT HOLDING GMBH (DE) | 2011-04-21 | — | — | US | claimed |
| EP-2004156-B1 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | POLYPLUS TRANSFECTION SA (FR) | 2011-01-26 | — | — | EP | claimed |
| WO-2005048944-A2 | ACTIVATABLE PHOTODYNAMIC THERAPY AGENTS | UNIVERSITY OF PENNSYLVANIA (US) | 2005-06-02 | — | — | WO | claimed |
| WO-2003038122-A2 | ASYMMETRICAL PROBES | FEBIT AG (DE) | 2003-05-08 | — | — | WO | claimed |
| US-12595486-B2 | Aptamers for personal health care applications | THE PROCTER & GAMBLE COMPANY (US) | 2026-04-07 | — | — | US | disclosed |
| US-12584135-B2 | Aptamers for personal health care applications | THE PROCTER & GAMBLE COMPANY (US) | 2026-03-24 | — | — | US | disclosed |
| US-12584137-B2 | Aptamers for personal health care applications | THE PROCTER & GAMBLE COMPANY (US) | 2026-03-24 | — | — | US | disclosed |
| EP-1185303-A1 | INHIBITION OF GASTRIC ACID PRODUCTION AND/OR SECRETION | Tachas, George (AU) | 2002-03-13 | — | — | EP | disclosed |
| WO-2002009509-A2 | INHIBITION OF GENE EXPRESSION USING POLYNUCLEOTIDE ANALOGUES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2000071164-A1 | INHIBITION OF GASTRIC ACID PRODUCTION AND/OR SECRETION | TACHAS GEORGE (AU) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584135-B2 | Aptamers for personal health care applications | ICAM1, VCAM1, EPCAM | MMP1 3579/4885MMP3 2294/4885MMP8 3099/4885 |
| US-12595486-B2 | Aptamers for personal health care applications | HAVCR2, EPCAM, ICAM1 | MMP1 4358/4885MMP3 2295/4885MMP8 3097/4885 |
| US-12584137-B2 | Aptamers for personal health care applications | HAVCR2, LDLR, ICAM1 | MMP1 4298/4885MMP3 2224/4885MMP8 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.